H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $73
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Regeneron (REGN)
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $76
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $59 to $76
Revolution Medicines Analyst Ratings
Barclays Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $72
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), UnitedHealth (UNH) and Edwards Lifesciences (EW)
Needham Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $59
Revolution Medicines Analyst Ratings
Revolution Medicines: Promising Phase 3 Progress and Strong RAS-ON Platform Drive Buy Rating
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $64
Revolution Medicines Price Target Cut to $64.00/Share From $78.00 by Stifel
Revolution Medicines Is Maintained at Buy by Stifel
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $76
Revolution Medicines Analyst Ratings
H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $73
J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $70
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $59 to $78
Revolution Medicines Is Maintained at Buy by Stifel
Analysts Conflicted on These Healthcare Names: Revolution Medicines (RVMD) and Genmab (GMAB)